West Pharmaceutical Services OCI Before Reclassifications, Net of Tax decreased by 117.3% to -$20.20M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 138.6%, from $52.30M to -$20.20M. This decline may warrant attention — for this metric, higher values are generally preferred.
Positive trends suggest favorable movements in currency or debt markets that are not yet realized in earnings.
Measures the total change in equity from non-owner sources that is excluded from net income, calculated before any recla...
Standard reporting component for all companies with international operations or significant debt portfolios.
tmo_oci_before_reclassifications_net_of_tax| Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$22.30M | -$23.60M | -$63.70M | -$76.00M | $14.20M | -$17.30M | -$42.80M | -$49.50M | -$25.00M | $80.30M | $52.30M | $117.00M | -$20.20M |
| QoQ Change | — | -5.8% | -169.9% | -19.3% | +118.7% | -221.8% | -147.4% | -15.7% | +49.5% | +421.2% | -34.9% | +123.7% | -117.3% |
| YoY Change | — | — | — | -240.8% | +160.2% | +72.8% | +43.7% | -448.6% | -44.5% | +287.6% | +205.7% | +568.0% | -138.6% |